Immunohistochemical Analysis with Pluripotent Stem Cell Specific Antibodies is Predictive of Survival in Colonic Carcinoma

摘要

Background: In some malignancies, the development of aggressive and metastatic potential often correlates with an increase in pluripotent cancer stem cells. Curemeta makes antibodies to targets that are uniquely expressed on pluripotent cancer stem cells. Our lead monoclonal IgG antibody, Bstrongomab, targets a cell surface glycoprotein on primitive cancer stem cells. We have shown that the antigen is expressed in a wide variety of solid tumors including: colon, pancreatic, breast, ovarian, prostate and lung carcinomas. This study focuses on a series of colonic carcinomas evaluating Bstrongomab staining and correlations with patient survival. An antibody drug conjugate, (ADC) against the target would be the ultimate goal and is being investigated.